The health technology landscape is evolving rapidly, particularly with the announcement that Advanced Machine Intelligence (AMI), a new venture founded by former Meta chief AI scientist Yann LeCun, has secured $1 billion in funding. This investment is poised to benefit Nabla, an AI documentation company closely linked to AMI, as it strives to carve out a competitive edge in healthcare automation.
Collaboration Between AMI and Nabla
The funding round for AMI aims to develop “world models” that enhance decision-making processes within healthcare. This partnership becomes significant as Nabla’s CEO, Alex LeBrun, also serves as the CEO of AMI, fostering a collaborative environment between the two organizations. Although there is currently no formal equity or licensing agreement, Nabla’s Chief Operating Officer, Delphine Groll, confirmed that the two companies are actively working together.
In a recent blog post, LeBrun, Groll, and Nabla’s Chief Technology Officer, Martin Raison, discussed the potential of world models in healthcare. They argue that these models learn to represent environments abstractly, similar to human reasoning. Unlike traditional probabilistic language models, the executives assert that this new approach will allow for “safe, deterministic, auditable decision-making,” which could offer a regulatory pathway for autonomous systems.
Last year, Nabla raised $70 million to support its growth initiatives and technological advancements. The collaboration with AMI may enhance its ability to innovate in a sector crowded with competitors attempting to streamline complex healthcare tasks.
Cadence to Enhance AI Utilization in Medicare
In another development within the healthcare sector, Cadence announced its participation in the Medicare ACCESS model, set to launch its first cohort in July. This initiative aims to align payments with health outcomes rather than individual services, a shift that has prompted public debate regarding the adequacy of reimbursement rates.
Cadence, known for its remote patient monitoring programs, plans to integrate AI into its services, making them more cost-effective. Chris Altchek, Cadence’s CEO, elaborated on the company’s existing AI capabilities and its strategy for safely deploying new clinical AI technologies, emphasizing compliance with the Food and Drug Administration.
Health Market Dynamics: Hims and Novo Nordisk
Telehealth provider Hims is adjusting its business strategy by shifting away from marketing compounded versions of GLP-1 medications for obesity and diabetes. Instead, it will focus on offering branded drugs from Novo Nordisk. This decision follows a patent infringement lawsuit that Novo Nordisk filed against Hims, which has now been dropped as part of the new arrangement.
Hims still retains the ability to offer compounded GLP-1 medications if deemed medically necessary by a healthcare provider, reflecting a careful navigation of the evolving regulatory landscape surrounding telemedicine and pharmaceutical distribution.
AI’s Impact on Healthcare Costs
Recent analyses from health insurers indicate that AI is contributing to rising healthcare costs. For instance, Blue Cross Blue Shield released a study focusing on claims related to postpartum hemorrhage, highlighting evidence of AI-driven coding practices. This development underscores the complex interplay between technological advancements and healthcare expenses.
Additionally, Talkspace, a mental health platform, is set to be acquired for $835 million by Universal Health Services, marking a significant move in the mental health sector following its public listing during the pandemic boom.
Reimagining Health Data as a Public Utility
A recent paper published in Science suggests that health and biomedical data should be treated similarly to other publicly extracted resources. The authors, including former ARPA-H Chief Data Officer Alastair Thomson, argue that patients should retain ownership of their data rather than allowing healthcare providers and electronic health record companies to claim it as their own. Thomson stated, “I believe the data belongs to the patients, and I think patients should be empowered to take control of their data.”
This proposal aims to redefine the governance of real-world health data, suggesting that a new framework could better serve public interests and enhance patient empowerment.
The ongoing developments at HIMSS, the prominent health tech conference, are likely to highlight these trends, showcasing innovations and collaborations that could shape the future of healthcare technology and policy.
